IGF1R and rhabdomyosarcoma: Moreover, with current IFN-α treatments and the added benefit already observed in a rhabdomyosarcoma tumor model with an anti-IGF-IR antibody enhancing the therapeutic effects of mTOR inhibitors or to specifically target IFN-α to a tumor, there is the potential to provide a new combination therapy for metastatic RCC.